Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 6Solid Tumor 4Mesothelioma 3Solid Tumors 2Pediatric Solid Tumors 2Advanced Solid Tumor 2Thymoma 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumor, Adult 1Retinoblastoma 1Refractory Solid Tumors 1Pleural Effusion, Malignant 1Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Malignant Solid Tumor 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Heart Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Childhood Solid Tumor 1Carcinoma, Hepatocellular 1

Interventions

ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE × Other solid neoplasm × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡